Business, energy, technology, markets and global industry news from Business News Today

Ascendis Pharma

PharmaDeviceNews Ascendis Pharma
A representative image illustrating Septerna Inc.’s SEP-479 research as the investigational oral PTH1R agonist shows a three-to-four-day half-life in Phase 1, supporting once-daily dosing for hypoparathyroidism.
Pharma & Biotech

SEP-479 clears first pharmacokinetic hurdle in pursuit of oral hypoparathyroidism therapy

SEP-479 shows a 3-to-4-day half-life in Phase 1, supporting once-daily oral dosing. See what Septerna must prove next in hypoparathyroidism.

Read More
A representative image illustrating pediatric growth monitoring as Ascendis Pharma’s weekly navepegritide and lonapegsomatropin combination sustains a 7.7-centimeter annualized growth rate through 78 weeks in children with achondroplasia.
Pharma & Biotech

Dual weekly therapy delivers sustained growth gains in children with achondroplasia

Weekly navepegritide combination sustains growth through 78 weeks in achondroplasia. Read what the small COACH trial shows and cannot prove.

Read More
Pharma & Biotech

Why Ascendis Pharma’s 182-week YORVIPATH data could matter for rare endocrine care

Find out how Ascendis Pharma’s YORVIPATH data could reshape hypoparathyroidism care and investor expectations.

Read More